StockData
Sionna Therapeutics, Inc. logo

Sionna Therapeutics, Inc. (SION) stock

SIONNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30
$3.07−0.05 (-1.60%)

Close on Nov 17, 2026Market cap $138.80MP/E –Yield –

Sionna Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Sionna Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $78.02M, up 31.5% year over year. For fiscal 2025 it was $60.26M, up 5.2% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$60.26M+5.2%
FY2024Dec 31, 2024$57.29M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$22.03M+37.3%
Q2 FY2026Jun 30, 2026$21.86M+42.1%
Q1 FY2026Mar 31, 2026$18.96M+38.7%
Q4 FY2025Dec 31, 2025$15.17M+6.4%
Q3 FY2025Sep 30, 2025$16.04M-34.7%
Q2 FY2025Jun 30, 2025$15.38M+86.8%
Q1 FY2025Mar 31, 2025$13.67M+33.7%
Q4 FY2024Dec 31, 2024$14.25M–
Q3 FY2024Sep 30, 2024$24.58M–
Q2 FY2024Jun 30, 2024$8.23M–
Q1 FY2024Mar 31, 2024$10.22M–

More Sionna Therapeutics figures

See a number that looks wrong?